rBIO Achieves Crucial Milestone on Mission to Lower the Cost of Insulin by 30%


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴ rBIO Achieves Crucial Milestone on Mission to Lower the Cost of Insulin by 30%
rBIO, an early-stage synthetic biology company focused on reducing the cost of prescription drugs, has announced its first in-lab milestone: synthetic production of human insulin.

rBIO, an early-stage synthetic biology company focused on reducing the cost of prescription drugs, has announced its first in-lab milestone: synthetic production of human insulin. With its genetic coding platform and process now proven, the company is now poised to upscale the production of insulin and to identify other prescription drugs that can be manufactured using rBIO's method for synthetically 'coding' microorganisms.

rBIO's approach applies recent breakthroughs in genetics and recombinant DNA science to design new strains of synthetic life capable of expressing a wide variety of peptide hormones.  

"We targeted insulin for our initial model because it checks two boxes: first, it's a specialty drug that is priced too high for many people who depend on it, and second its supply chain is vulnerable," said Cameron Owen, founder, and CEO of rBIO. "Our goal is to re-shore insulin manufacturing to the USA and make this crucial hormone available at a lower cost for the millions of Americans suffering from diabetes."

With lab-scale production of human insulin achieved, the next step is to increase insulin yields prior to seeking FDA approval. Looking ahead, rBIO has developed a shortlist of eight drugs that can be synthesized with this unique coding approach. "Our results with insulin clearly demonstrate that our technology works, so we're looking to apply this approach for epinephrine and erythropoietin, among others," added Owen.

"A wide array of biological products can be synthesized with this approach," said Dr. Debanjan Dhar, professor of medicine at the University of California, San Diego. "Single-celled organisms like yeast, bacteria, and algae can be exploited to drive the next manufacturing boom of biological products needed to meet patient demand for crucial drugs."

Pharmaceuticals are a major concern for national security, an issue that has received heightened prominence during the current COVID-19 pandemic. According to the FDA, 1,079 facilities worldwide produce the 370 drugs marketed in the US that are on the World Health Organization's Essential Medicines List. However, just 21 percent of those facilities are based in the United States.

About rBIO
rBIO is a biotech startup focused on applying recombinant DNA science to reduce the cost of prescription drugs. The company was formed by a team from Johns Hopkins Carey Business School and a team of scientists whose backgrounds include genetics, bioengineering, and bioinformatics. Based in San Francisco, rBIO is privately funded.

Tags : #rBIONewsUpdate17Dec2020 #rBIO #syntheticbiologycompany #humaninsulin #DNA #CameronOwen #diabetes #FightAgainstDiseases #UniversityofCalifornia

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026